Skip to content
- Preparing for Tuberculosis Vaccine M72/AS01EImplementation: A Global Demand Forecast and Key Influential Factors. Kallenberg J, Milea D, Breuer T, Philippot A. Infect Dis Ther. 2026 May;15(5):1263-1279. doi: 10.1007/s40121-026-01319-2. Epub 2026 Feb 25.
- Enhanced tuberculosis control via leveraging dendritic cell-mediated Th1 responses in preventive and immunotherapeutic vaccine strategies. Kim H, Kim JS, Kwon KW, Kim WS, Park M, Ha SJ, Choi S, Kim J, Shin SJ. J Adv Res. 2026 May;83:1061-1081. doi: 10.1016/j.jare.2025.07.056. Epub 2025 Jul 30.
- ID93 + GLA-3M-052-LS vaccine candidate administered by heterologous routes improves BCG efficacy against TB. Voigt E, Alsharaydeh A, Kasal DN, Jennewein MF, Brandt DS, Lin S, Singh J, Bakken J, Mohamath R, Fusco P, Torrelles JB, Beamer G, Fox CB. Front Immunol. 2026 May 1;17:1797767. doi: 10.3389/fimmu.2026.1797767.
- Recombinant Immunogens Designed by AI Epitope Prioritization Confer Protection Against Mycobacterium tuberculosis. Fang N, Chen A, Zhang Z, Ye M, Pan J, Huang W, Wang D, Hu Z, Fan X, Zhu B, Wang Y, Zhao G, Zhang L, Li J. Vaccines (Basel). 2026 May 1;14(5):408. doi: 10.3390/vaccines14050408. PMID: 42188779; PMCID: PMC13211660.
- A Highly Protective Live-Attenuated Vaccine Generated by Targeted Deletion of the Mycobacterium bovisVirulence Factor VapC40. Ge X, Wang H, Liu D, Dong Y, Li L, Shen P, Li Y, Zhang J, Zhou X, Yue R. Int J Mol Sci. 2026 May 1;27(9):4067. doi: 10.3390/ijms27094067.
- Superior protection against tuberculosis using heterologous mRNA nanoadjuvant vaccines. Touray BJB, Faburay AK, Mohamed FF, Abdelgayed SS, Talaat AM. NPJ Vaccines. 2026 May 2. doi: 10.1038/s41541-026-01476-y. Epub ahead of print.
- How Mycobacterium tuberculosisSubverts Innate and Adaptive Immunity and Their Crosstalk: Implications for Vaccine Design. Prasad GVRK, Philips JA. Vaccines (Basel). 2026 May 2;14(5):414. doi: 10.3390/vaccines14050414.
- mRNA vaccine development for tuberculosis: antigen design, immune mechanisms, and translational challenges. Abuhassan Q, Shuheil MA, Singh NSS, Raj PB, Ganesan S, Ray S, Sohal HS, Waleed OS, Muminova S, Latipova M, Begmatova D. Arch Microbiol. 2026 May 5;208(7):369. doi: 10.1007/s00203-026-04929-z.
- rBCG::PUMA exhibits enhanced immunogenicity compared to BCG in mice. Song D, Ji J, Yang S, Chen Z, Liu J, Chen Y, Li G. Microb Pathog. 2026 Jul;216:108541. doi: 10.1016/j.micpath.2026.108541. Epub 2026 May 6.
- Applications of humanized mice in Mycobacterium tuberculosisinfections (Review). Han B, Liu F, Long J, Wang J, Cui Y, Yang H. Mol Med Rep. 2026 July;34(1):188. doi: 10.3892/mmr.2026.13898. Epub 2026 May 8.
- Domain arrangement-driven immunogenicity of a computationally designed mRNA vaccine targeting PPE68, IrtA, and PE9 of Mycobacterium tuberculosis. Dorbutr T, Stylianou E, McShane H, Pinpathomrat N. Sci Rep. 2026 May 11. doi: 10.1038/s41598-026-47531-5. Epub ahead of print.
- Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01E-4tuberculosis vaccine. Dagnew AF, Noble R, Cinar A, Burhan E, Churchyard G, Fairlie L, Hanekom WA, Muyoyeta M, Mwandumba HC, Nduba V, Curran M, Schmidt AC. Vaccine. 2026 May 12;85:128690. doi: 10.1016/j.vaccine.2026.128690. Epub ahead of print.
- Construction and characterization of novel Mycobacterium tuberculosis-derived triple and quadruple knockout vaccines against tuberculosis. Garnica O, Veerapandian R, Das K, Mishra A, Rawat V, Carmona A, Chauhan V, Kumar R, Chacon J, Khan A, Ramos EI, Gadad SS, Jagannath C, Dhandayuthapani S. Infect Immun. 2026 May 12;94(5):e0050025. doi: 10.1128/iai.00500-25. Epub 2026 Apr 21.
- How to introduce a new TB vaccine in adolescents and adults: Insights from Key Stakeholders in Mozambique, Southern Africa. Lima AV, Kim D, Acácio S, Fernandes Q, José B, Lopman B, García-Basteiro AL, Nelson KN. medRxiv [Preprint]. 2026 May 13:2026.05.10.26352803. doi: 10.64898/2026.05.10.26352803.
- Targeted Tuberculosis (TB) Vaccination Strategies in the United States: A Modeling Study. Rothman JE, Castro KG, Lopman BA, Gandhi NR, Nelson KN. medRxiv [Preprint]. 2026 May 14:2026.05.11.26352914. doi: 10.64898/2026.05.11.26352914.
- Number Needed to Vaccinate with a Novel Tuberculosis Vaccine to Prevent Tuberculosis in High-Risk Populations, United States. Rothman JE, Castro KG, Lopman BA, Gandhi NR, Nelson KN.medRxiv [Preprint]. 2026 May 15:2026.05.11.26352950. doi: 10.64898/2026.05.11.26352950.
- Rv2656c: A Potential Candidate Antigen Associated with Latent Tuberculosis Infection.ap2 Du Y, He P, Dang W, Zhou T, Song Y, Li X, Zhao Y, Li F, Guo A, Zhu B. Vaccines (Basel). 2026 May 15;14(5):442. doi: 10.3390/vaccines14050442.
- mu BCG administration induces transcription factor signature in CD4+T cells that cooperates with IL-12 signaling to drive antiviral Th1 differentiation. Wang R, Zhao Y, Yang J, Luo R, Sun W, Zhang M, Liu X, Hou Y, Cao P, Li E. Vaccine. 2026 May 16;85:128720. doi: 10.1016/j.vaccine.2026.128720. Epub ahead of print.
- The influence of murine cytomegalovirus infection on susceptibility to mycobacterial infection. Li S, Hutchings C, Korompis M, De Voss C, Ateere A, Satti I, Klenerman P, McShane H, Stylianou E. iScience. 2026 Mar 27;29(5):115518. doi: 10.1016/j.isci.2026.115518.
- Lung mucosal and systemic responses at single-cell resolution in an aerosolized Mycobacterium bovis BCG human challenge model. Li S, Morrison H, Duta M, Marshall JL, Harris SA, He W, Ateere A, Nassanga B, Satti I, McShane H. Cell Rep Med. 2026 May 21:102830. doi: 10.1016/j.xcrm.2026.102830. Epub ahead of print.
- Understanding adjuvant supply chains for new TB and malaria vaccines. Gotham D, Frick M, Harrington M. Vaccine. 2026 May 22;82:128609. doi: 10.1016/j.vaccine.2026.128609. Epub 2026 Apr 22.
- Targeted delivery of the BCG vaccine to dendritic cells improves protective efficacy against Mycobacterium tuberculosis. Counoupas C, Nisa A, Baker L, Pinto R, Bhattacharyya N, Demangel C, Britton WJ, Triccas JA. Vaccine. 2026 May 22;86:128753. doi: 10.1016/j.vaccine.2026.128753. Epub ahead of print.
- A novel multiepitope peptide vaccine with intrinsic adjuvant confers protective immunity in mice against tuberculosis. Sharma M, Kumar D, Bedi AK, Yadav P, Bhatt P, Kathait S, Basil MV, Rani M, Kulshrestha R, Verma AK, Sharma M, Sharma S. Microb Pathog. 2026 May 24;217:108589. doi: 10.1016/j.micpath.2026.108589. Epub ahead of print.
- Construction and immunogenicity evaluation of a tuberculosis subunit vaccine based on fusion protein AP2 and novel adjuvant ASM. Wang R, Wang X, Kong L, Sun Q, Wu J, Liu G, Zhou M, Ju J, Zhang Z, Xu Y, Zhong Q. Arch Microbiol. 2026 May 25;208(8):403. doi: 10.1007/s00203-026-04975-7.
- Advancing national preparedness for the introduction of novel tuberculosis vaccines in South Africa: policy, evidence, and system readiness insights from a national workshop. Ndjeka N, Subrayen P, Hanekom WA, Jassat W, Luabeya AKK, Mkhondo N, Muloiwa R, Tisile P, Ntshiqa T, Boffa J, Giersing B. 2026 May 26;86:128755. doi: 10.1016/j.vaccine.2026.128755. Epub ahead of print.
- Oxidative modifications of tuberculosis antigen Ag85B alter its T cell antigenicity. Clemen R, Corleis B, Dallenga T, Schulan P, Schaible UE, Bekeschus S. Redox Biol. 2026 May 28;94:104233. doi: 10.1016/j.redox.2026.104233. Epub ahead of print.
